<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01532817</url>
  </required_header>
  <id_info>
    <org_study_id>BC-US-06</org_study_id>
    <nct_id>NCT01532817</nct_id>
  </id_info>
  <brief_title>Relief of Acute Bronchoconstriction/Asthma Using the Non-Invasive AlphaCore Device</brief_title>
  <official_title>Non-Invasive Neurostimulation of the Vagus Nerve With the AlphaCore™ Device, for the Relief of Acute Bronchoconstriction Due to Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ElectroCore LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ElectroCore LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this pilot study is to collect preliminary clinical data related to the safety
      and preliminary clinical benefits of non-invasive vagal nerve stimulation with the AlphaCore™
      device for the relief of acute bronchoconstriction due to asthma.

      Up to 30 subjects who meet all inclusion/exclusion criteria and consent to participate in the
      study may be enrolled at up to 5 investigational (study) sites. The study sites are clinic
      settings capable of treating any potential complications of bronchoconstriction, an acute
      exacerbation of asthma, and any emergencies associated with use of the investigational
      device.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will be screened, consented and enrolled at the first visit. Subjects will return to
      the second visit where they are experiencing shortness of breath and will be treated with the
      alphacore. Breathing and vital signs will be measured before, during and after the
      stimulation. The study is concluded on the third visit, 7 days later.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety- Number of Participants With Adverse Events</measure>
    <time_frame>From time subject signs the consent through the 1-week follow-up visit</time_frame>
    <description>Safety- number of participants with adverse events, including device-related, serious or unanticipated</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>alphacore</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>noninvasive neurostimulation of the vagus nerve</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>AlphaCore</intervention_name>
    <description>A single 90 second stimulation to the vagus nerve on the right side of the neck</description>
    <arm_group_label>alphacore</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA: VISIT 1

          1. Is able to give written Informed Consent.

          2. Is between the ages of 18 and 65 years, male or female.

          3. Has a known history of mild to moderate asthma for at least 1 year as defined by GINA
             Guidelines.

          4. Is using a short acting beta-agonist for relief/rescue of asthma..

          5. At Visit 1, demonstrates current or historical (within 1 year) FEV1 reversibility of
             at least 12% (and 200ml) or greater within 15-30 minutes following administration of 4
             inhalations of albuterol.

        EXCLUSION CRITERIA: VISIT 1

          1. Has a history of lung cancer, chronic obstructive pulmonary disease (COPD), or other
             co-morbidity associated with irreversible narrowing of the airways.

          2. Has an abscess or other infection or lesion (including lymphadenopathy) at the
             AlphaCore™ treatment site.

          3. Has known or suspected moderate to severe atherosclerotic cardiovascular disease,
             carotid artery disease (e.g. bruits or history of TIA or CVA) or congestive heart
             failure (CHF).

          4. Has suspected or confirmed sepsis.

          5. Has a clinically significant irregular heart rate or rhythm.

          6. Has experienced recent clinically significant changes in blood pressure, has
             uncontrolled high blood pressure, or is presently receiving pressors to maintain blood
             pressure.

          7. Is currently implanted with an electrical and/or neurostimulator device, including but
             not limited to cardiac pacemaker, defibrillator, vagal neurostimulator, deep brain
             stimulator, spinal stimulator, bone growth stimulator, or cochlear implant.

          8. Has a history of carotid endarterectomy or vascular neck surgery on the right side.

          9. Has been implanted with metal cervical spine hardware.

         10. Has a recent or repeated history of syncope.

         11. Has a recent or repeated history of seizures.

         12. Is pregnant or nursing, or of childbearing years and is unwilling to use an accepted
             form of birth control.

         13. Is participating in any other therapeutic clinical investigation or has participated
             in a clinical trial in the preceding 30 days.

         14. Belongs to a vulnerable population or has any condition such that his or her ability
             to provide informed consent, comply with follow-up requirements, or provide
             self-assessments is compromised (e.g., homeless, developmentally disabled, prisoner).

         15. Is a relative of or an employee of the Investigator or the clinical study site.

        INCLUSION CRITERIA: VISIT 2

          1. No changes have occurred in the patient's health or status relative to the original
             inclusion and exclusion criteria and the patient continues to be eligible for
             participation in the study.

          2. Either (i) develops subjective symptoms of asthma (wheezing, shortness of breath,
             cough) for which the patient would normally self-medicate with a short acting beta
             agonist, and/or (ii) documents a drop of 20% from screening PEF scores as recorded in
             their patient diary.

          3. At Visit 2, FEV1 is the same or lower than the screening FEV1 previously measured at
             visit 1 or the PEF is the same or lower than the screening previously measured at
             Visit 1.

        EXCLUSION CRITERIA: VISIT 2

          1. The patient self-administered a short-acting beta agonist within 6 hours prior to
             onset of asthma symptoms.

          2. The patient induced an asthma exacerbation by withholding their pre-treatment
             medication used for exercise-induced bronchoconstriction (EIB).

          3. Has signs and symptoms of asthma instability at Visit 2:

               -  Lung Function: FEV1 &lt; 50 % predicted.

               -  Signs and symptoms of extreme respiratory distress at rest.

               -  Rapid deterioration in respiratory status (sudden change in respiratory rate,
                  decrease in oxygen saturation, change in consciousness, etc.).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Erico</last_name>
    <role>Study Chair</role>
    <affiliation>ElectroCore LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Allergy and Asthma</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CRI</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55402</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vital Prospects Clinical Research Institute</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 10, 2012</study_first_submitted>
  <study_first_submitted_qc>February 10, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 15, 2012</study_first_posted>
  <results_first_submitted>March 7, 2018</results_first_submitted>
  <results_first_submitted_qc>April 6, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">April 9, 2018</results_first_posted>
  <disposition_first_submitted>February 23, 2016</disposition_first_submitted>
  <disposition_first_submitted_qc>January 18, 2018</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">January 25, 2018</disposition_first_posted>
  <last_update_submitted>April 6, 2018</last_update_submitted>
  <last_update_submitted_qc>April 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Alphacore</title>
          <description>noninvasive neurostimulation of the vagus nerve
AlphaCore: A single 90 second stimulation to the vagus nerve on the right side of the neck</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Open label 30 patient population</population>
      <group_list>
        <group group_id="B1">
          <title>Alphacore</title>
          <description>noninvasive neurostimulation of the vagus nerve
AlphaCore: A single 90 second stimulation to the vagus nerve on the right side of the neck</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <title>Age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30" lower_limit="20" upper_limit="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Safety- Number of Participants With Adverse Events</title>
        <description>Safety- number of participants with adverse events, including device-related, serious or unanticipated</description>
        <time_frame>From time subject signs the consent through the 1-week follow-up visit</time_frame>
        <population>Open label study 30 participants</population>
        <group_list>
          <group group_id="O1">
            <title>Alphacore</title>
            <description>noninvasive neurostimulation of the vagus nerve
AlphaCore: A single 90 second stimulation to the vagus nerve on the right side of the neck</description>
          </group>
        </group_list>
        <measure>
          <title>Safety- Number of Participants With Adverse Events</title>
          <description>Safety- number of participants with adverse events, including device-related, serious or unanticipated</description>
          <population>Open label study 30 participants</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From screening visit 1 to visit 3 follow up, 9 weeks.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Alphacore</title>
          <description>noninvasive neurostimulation of the vagus nerve
AlphaCore: A single 90 second stimulation to the vagus nerve on the right side of the neck</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction to food</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Viral respiratory syndrome</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Local site neck pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Sensation of muscle tightness/spasm from right ear to right wrist</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Sensation of musculoskeletal tenseness/tightness through upper body</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Torticollis muscular</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Upper body jitteriness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Tingling sensation on right side of neck</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hoarseness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Increased chest congestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Increased mucus in post oropharynx</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Faint localised area of erythema on anterior biceps bilaterally</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Right neck skin itching</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Affairs</name_or_title>
      <organization>electroCore LLC</organization>
      <phone>+1 973 355 6683</phone>
      <email>clinical@electrocorellc.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

